
Integrum Q1 - Good start to fiscal year 2023e

Redeye is encouraged to see Integrum delivering well on sales throughout the challenging summer months. We believe fiscal year 2023e will propel Integrum towards the SEK100m sales mark as we anticipate increasing US surgery volumes on the back of its established centres. We reiterate our fair value range and emphasise that the current share price levels suggest a limited downside risk, offering a hefty upside potential mainly driven by quarterly reports.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Integrum Q1 - Good start to fiscal year 2023e](#)